Zai Lab has a total of 23 patents globally, out of which 13 have been granted. Of these 23 patents, more than 82% patents are active. China is where Zai Lab has filed the maximum number of patents, followed by Europe. Parallelly, China seems to be the main focused R&D centre.
Zai Lab was founded in the year 2014 by Samantha DU. The company is a biopharmaceutical company which is focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients. As of December 2022, Zai Lab has a market cap of $3.03 Billion.
Do read about some of the most popular patents of Zai Lab which have been covered by us in this article and also you can find Zai Lab patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Zai Lab patent portfolio.
How many patents does Zai Lab have?
Zai Lab has a total of 23 patents globally. These patents belong to 13 unique patent families. Out of 23 patents, 19 patents are active.
How Many Patents did Zai Lab File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Zai Lab Applications Filed | Zai Lab Patents Granted |
| 2022 | – | 4 |
| 2021 | – | 2 |
| 2020 | 7 | 6 |
| 2019 | 4 | – |
| 2018 | 11 | – |
| 2012 | – | 1 |
How many Zai Lab patents are Alive/Dead?
How Many Patents did Zai Lab File in Different Countries?
Where are Research Centres of Zai Lab Patents Located?
List of Zai Lab Patents
| Zai Lab Patents | Title |
| ES2923138T3 | procedure to prepare an intermediate of the Niraparib antitumor and intermediate |
| EP3694836B1 | Process for preparing intermediate of Anti-tumor drug niraparib and intermediate thereof |
| DE602018036876T2 | METHOD OF MANUFACTURE OF AN INTERMEDIATE OF ANTI-TUMORS DRUG NIRAPARIB AND INTERMEDIATE THEREOF |
| IT202200044635T2 | process FOR THE PREPARATION OF AN INTERMEDIATE OF THE ANTI-CANCER DRUG NIRAPARIB AND ITS INTERMEDIATE. |
| CN113423735A | Anti-claudin antibodies and uses thereof |
| KR102221087B1 | Intermediate manufacturing method and intermediate for synthesizing anti-tumor drug niraparib |
| US10927077B2 | Process for preparing intermediate of anti-tumor drug niraparib and intermediate thereof |
| IL273890A | Process for preparing intermediate of Anti-tumor drug niraparib and intermediate thereof |
| CN306031911S | Medicine Packaging Box (2) |
| CN306031912S | Medicine Box(3) |
| CN306031910S | Medicine Box (1) |
| HK40015810A | Cd47 antigen binding unit and uses thereof |
| CN305841944S | Medicine Box (2) |
| CN305841945S | Medicine Box (1) |
| IN202047018936A | Process for preparing intermediate of Anti-tumor drug niraparib and intermediate thereof |
| WO2020114480A1 | Anti-claudin antibodies and uses thereof |
| CN111253486A | Anti-PD-1 antibody and application thereof |
| WO2020063823A1 | Anti-pd-1 antibodies and uses thereof |
| CN109265390B | A kind of preparation method and intermediate for the intermediate of synthetic antineoplastic drug niraparib |
| CN110461872A | CD47 antigen binding unit and uses thereof |
| WO2019072237A1 | Process for preparing intermediate of Anti-tumor drug niraparib and intermediate thereof |
| WO2018137705A1 | Cd47 antigen binding unit and uses thereof |
| CN101564420B | Chinese medicinal herb composition for treating skin disease |